mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma

Kerr, Darcy A.; Busarla, Satya Vara Prasad; Gimbel, Devon C.; Sohani, Aliyah R.; Nazarian, Rosalynn M.

doi:10.1016/j.humpath.2017.05.002

Cited by 17 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, CNI conversion to sirolimus improves pt‐KS prognosis in renal recipients without impairing graft function . In KS samples, vascular endothelial growth factor (VEGF) and mTOR pathways were shown to be upregulated with high expression of VEGF, phospho‐mTOR, and phospho‐P70S6K, supporting the rational for the use of mTOR inhibitor in pt‐KS, In our series, only patient 1 had conversion of tacrolimus to sirolimus because of immunosuppressive management of pt‐KS depended on era and most patients had first transplant before 2000 (Table ). For the same reason, maintenance immunosuppression regimen used CNI, mycophenolate mofetil, and steroids for the second transplantation.…”

Section: Discussionmentioning

confidence: 58%

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Bohelay

Arzouk

Lévy

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

This retrospective study concerned 8 patients with post-transplantation Kaposi's sarcoma (pt-KS) after a first kidney transplant who later had a second kidney transplantation. Pt-KS was widespread, with lymph node or visceral involvement in 7 cases. Complete remission was observed in 6 cases and partial remission in 2. After the second kidney transplantation, only 2 cases showed recurrence of skin KS, one with previous complete remission of KS and one with partial remission. The mean delay between stability or complete remission of KS and retransplantation was 2.0 and 7.3 years in patients with and without relapse, respectively. Both recurrent cases showed complete KS remission after tapering immunosuppression therapy and/or switching a calcineurin inhibitor to a mammalian target of rapamycin inhibitor. We compared these 8 cases to 24 controls who had undergone 2 kidney transplantations but did not have KS, matching on sex, age and phototype. Cases and controls did not differ in graft function or survival. A second kidney transplantation may be possible after pt-KS and has acceptable risk, especially after a long complete remission of pt-KS.

show abstract

Section: Discussionmentioning

confidence: 58%

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Bohelay

Arzouk

Lévy

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…It has also been shown to be expressed in vascular endothelial cells and to interact with vascular endothelial growth factor (VEGF) [16]. Angiogenesis is an important feature in the formation of Kaposi sarcoma lesions, and the tumors overexpress VEGF [17]. Based on GTEx data, SCUBE2 is most expressed in bladder, prostate, and breast tissues (Supplementary Figure 4).…”

Section: Discussionmentioning

confidence: 99%

Candidate Predisposition Variants in Kaposi Sarcoma as Detected by Whole-Genome Sequencing

Rinne

Sipilä

Sulo

et al. 2019

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Familial clustering of classic Kaposi sarcoma (CKS) is rare with, approximately 100 families reported to date. We studied 2 consanguineous families, 1 Iranian and 1 Israeli, with multiple cases of adult CKS and without overt underlying immunodeficiency. We performed genome-wide linkage analysis and whole-genome sequencing to discover the putative genetic cause for predisposition. A 9-kb homozygous intronic deletion in RP11-259O2.1 in the Iranian family and 2 homozygous variants, 1 in SCUBE2 and the other in CDHR5, in the Israeli family were identified as possible candidates. The presented variants provide a robust starting point for validation in independent samples.

show abstract

“…Der Morbus Kaposi ist durch Neoangiogenese, Vorhandensein von Spindelzellen sowie Überexpression von Vascular Endothelial Growth Factor (VEGF, HHV-8 mediiert) gekennzeichnet [8]. Man vermutet, dass für die Entstehung eines Kaposi-IRIS, neben einer hohen HIV-Viruslast (> 5 log 10 Kopien/ml) und VEGF auch Makrophagen, Monozyten und eine Dysregulation von mTOR, Platelet-Derived Growth Factor (PDGF), c-kit und IL-6 verantwortlich sind [8][9][10].…”

Section: Clinical Letterunclassified

Immun‐Rekonstitutions‐Inflammations‐Syndrom (IRIS) bei einem HIV‐positiven Patienten mit Pneumocystis‐jirovecii‐Pneumonie (PjP) und Morbus Kaposi

Dewasurendra

Kitchen

Gisinger

et al. 2020

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma

Cited by 17 publications

References 30 publications

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Outcome of second kidney transplantation in patients with previous post‐transplantation Kaposi's sarcoma: A French retrospective study

Candidate Predisposition Variants in Kaposi Sarcoma as Detected by Whole-Genome Sequencing

Immun‐Rekonstitutions‐Inflammations‐Syndrom (IRIS) bei einem HIV‐positiven Patienten mit Pneumocystis‐jirovecii‐Pneumonie (PjP) und Morbus Kaposi

Contact Info

Product

Resources

About